Literature DB >> 7214694

Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum.

Y M Chan, S J Soldin, J M Swanson, C M Deber, J J Thiessen, S Macleod.   

Abstract

A gas chromatographic/mass spectrometric (GG/MS) procedure for the determination of methylphenidate in 1 mL of serum or plasma is reported employing ethylphenidate as internal standard. A 50/50 (V/V) mixture of benzene and hexane is used to extract the methylphenidate and ethylphenidate from plasma. After evaporation of solvent the residue is redissolved in 50 microL hexane. Methyl- and ethylphenidate are then derivatized by the addition of 50 ML of trifluoroacetic anhydride and the TFA derivatives are injected into a quadrupole GC/MS for analysis. This method has a lower limit of sensitivity for methylphenidate of 2.0 micrograms/L. The between-day precision study yielded coefficients of variation of 10.4% and 14.8% at methylphenidate concentrations of 25.6 and 5.2 micrograms/L respectively. The assay has been used to investigate the pharmacokinetics of methylphenidate administered to 6 children for treatment of hyperkinesis. The study yielded ranges for volume of distribution, elimination half-life, and total body clearance of 5.0-6.8 L/kg, 1.6-2.7 hours, and 1.4-2.9 L/kg-hr respectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7214694     DOI: 10.1016/s0009-9120(80)80007-5

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

Review 1.  Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance.

Authors:  James H Ho; George P Bailey; John R H Archer; Paul I Dargan; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2015-07-22       Impact factor: 2.953

2.  Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity.

Authors:  C P Collier; S J Soldin; J M Swanson; S M MacLeod; F Weinberg; J G Rochefort
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

3.  A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Kennerly S Patrick; Jennifer L Donovan; C Lindsay DeVane; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-19       Impact factor: 3.205

4.  Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers.

Authors:  T Aoyama; H Kotaki; T Sasaki; Y Sawada; Y Honda; T Iga
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.

Authors:  Kennerly S Patrick; Timothy R Corbin; Cristina E Murphy
Journal:  J Pharm Sci       Date:  2014-10-09       Impact factor: 3.534

6.  Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates.

Authors:  Xiaoxia Yang; Suzanne M Morris; Jeffery M Gearhart; Christopher D Ruark; Merle G Paule; William Slikker; Donald R Mattison; Benedetto Vitiello; Nathan C Twaddle; Daniel R Doerge; John F Young; Jeffrey W Fisher
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

7.  Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults.

Authors:  Xiaoxia Yang; John Duan; Jeffrey Fisher
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

Review 8.  From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.

Authors:  Francesco Paolo Busardò; Chrystalla Kyriakou; Luigi Cipolloni; Simona Zaami; Paola Frati
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.